ACHV vs. TKNO, VNRX, ABIO, AWH, ICCC, AMWL, PIII, CLPT, CO, and SYRS
Should you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include Alpha Teknova (TKNO), VolitionRx (VNRX), ARCA biopharma (ABIO), Aspira Women's Health (AWH), ImmuCell (ICCC), American Well (AMWL), P3 Health Partners (PIII), ClearPoint Neuro (CLPT), Global Cord Blood (CO), and Syros Pharmaceuticals (SYRS). These companies are all part of the "medical" sector.
Achieve Life Sciences (NASDAQ:ACHV) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations, community ranking and risk.
Achieve Life Sciences has higher earnings, but lower revenue than Alpha Teknova. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Alpha Teknova, indicating that it is currently the more affordable of the two stocks.
In the previous week, Achieve Life Sciences had 6 more articles in the media than Alpha Teknova. MarketBeat recorded 6 mentions for Achieve Life Sciences and 0 mentions for Alpha Teknova. Achieve Life Sciences' average media sentiment score of 0.37 beat Alpha Teknova's score of 0.00 indicating that Achieve Life Sciences is being referred to more favorably in the media.
33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are held by institutional investors. 2.0% of Achieve Life Sciences shares are held by company insiders. Comparatively, 15.2% of Alpha Teknova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Achieve Life Sciences presently has a consensus price target of $17.25, suggesting a potential upside of 279.96%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Achieve Life Sciences is more favorable than Alpha Teknova.
Achieve Life Sciences received 323 more outperform votes than Alpha Teknova when rated by MarketBeat users. Likewise, 70.15% of users gave Achieve Life Sciences an outperform vote while only 30.00% of users gave Alpha Teknova an outperform vote.
Achieve Life Sciences has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500.
Achieve Life Sciences has a net margin of 0.00% compared to Alpha Teknova's net margin of -100.26%. Alpha Teknova's return on equity of -38.12% beat Achieve Life Sciences' return on equity.
Summary
Achieve Life Sciences beats Alpha Teknova on 11 of the 17 factors compared between the two stocks.
Get Achieve Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Achieve Life Sciences Competitors List
Related Companies and Tools
